SDC-TRAP Conjugates for Targeted Hsp90 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapeutic treatments for diseases like cancer are unsatisfactory due to limitations from undesired side effects and toxicity, particularly when targeting heat shock proteins such as Hsp90, which are overexpressed in cancer cells, leading to challenges in selectively delivering therapeutic agents while minimizing harm to normal cells.
Innovation Solution
Development of Small molecule Drug Conjugates that are TRAPped intracellularly (SDC-TRAPs), which consist of an effector moiety conjugated to a binding moiety that selectively targets cells overexpressing specific proteins like Hsp90, allowing for targeted delivery and retention within target cells, thereby minimizing systemic toxicity and maximizing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapeutic treatments are used to target cancer cells, then therapeutic effect is achieved, but systemic toxicity and side effects increase
Solution Approach 1:
The chemotherapeutic agent is segmented into two functional components: a binding moiety that specifically recognizes and binds to Hsp90 in cancer cells, and an effector moiety that delivers the cytotoxic effect. This segmentation enables selective delivery of the therapeutic effect to target cells while minimizing exposure of healthy cells to the toxic agent.
Solution Approach 2:
The binding moiety acts as an intermediary that mediates between the effector moiety and the Hsp90 target. It selectively binds to Hsp90 in cancer cells and facilitates the delivery of the effector moiety to the target, thereby enabling specific therapeutic action while reducing systemic toxicity.
2Manufacturing precision
If Hsp90 inhibitors are used to target cancer cells, then selective targeting of overexpressed Hsp90 is achieved, but toxicity profile worsens
Solution Approach 1:
The conjugate exhibits local quality by concentrating the therapeutic effect specifically at the target site (Hsp90 in cancer cells) through selective binding. The binding moiety ensures that the effector moiety is delivered predominantly to cells overexpressing Hsp90, creating a localized therapeutic action that spares healthy tissues from toxicity.
Solution Approach 2:
The invention employs a composite structure combining the binding moiety (specific to Hsp90) and the effector moiety (cytotoxic agent) into a single conjugate molecule. This composite design allows the molecule to simultaneously achieve specific targeting and potent therapeutic effect while reducing the required dose and associated toxicity.
3Quantity of substance
If therapeutic moieties are delivered systemically, then broad coverage is achieved, but selectivity for target cells decreases
Solution Approach 1:
The binding moiety performs preliminary action by specifically recognizing and binding to Hsp90 on or in target cancer cells before the effector moiety exerts its cytotoxic effect. This preliminary binding step ensures that the therapeutic agent is selectively activated or retained at the target site, enhancing cellular selectivity while maintaining broad distribution capability.
Data Source
AI summary
The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.